Amphastar Pharmaceuticals, Inc.
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $719.9M
- Net income
- $98.1M
- Total assets
- $1.6B
- Market cap
- $870.4M
- Gross margin
- 49.5%
- Operating margin
- 19.5%
- Net margin
- 13.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $719.9M
- Cost of revenue
- $363.8M
- Gross profit
- $356.1M
- Operating expenses
- $215.7M
- Operating income
- $140.4M
- Income tax
- $25.5M
- Net income
- $98.1M
- EPS (basic)
- $2.10
- EPS (diluted)
- $2.03
Balance sheet
- Total assets
- $1.6B
- Current assets
- $636.0M
- Total liabilities
- $840.5M
- Current liabilities
- $158.2M
- Shareholders’ equity
- $788.8M
Cash flow
- Operating cash flow
- $156.1M
- Investing cash flow
- -$70.3M
- Financing cash flow
- -$67.4M
- Net cash flow
- $18.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $870.4M
- P/E ratio
- 9.6
- EPS (diluted)
- $2.03
- Shares outstanding
- 44.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 25, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $98.1M in FY2025.
- Revenue grew 106% from FY2020 to FY2025.
- Gross margin of 49.5%, net margin 13.6%.
- Trading 37% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 9.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Amphastar Pharmaceuticals, Inc..
Write a review
News about Amphastar Pharmaceuticals, Inc.
News & sentiment via Polygon.io
